期刊文献+

不同剂量丙磺舒对头孢克罗药物动力学的影响 被引量:3

Influence of probenecid on pharmacokinetics of cefaclor
下载PDF
导出
摘要 目的 :观察不同剂量丙磺舒 (Pro)对头孢克罗 (Cef)药动学的影响 ,为两者联用提供依据。方法 :家兔 30只随机分成 5组 ;Cef 5 0mg·kg- 1组 ,Cef5 0mg·kg- 1+Pro 5 0mg·kg- 1组 ,Cef 5 0mg·kg- 1+Pro 10 0mg·kg- 1组 ,Cef 5 0mg·kg- 1+Pro2 0 0mg·kg- 1组 ,Cef 2 5mg·kg- 1+Pro 10 0mg·kg- 1组。灌胃给药后于不同时间股静脉取血 ,HPLC法测定Cef血药浓度 ,NDST程序计算药动学参数。结果 :在给予Cef 5 0mg·kg- 1条件下 ,随Pro联用剂量的增大 ,Cef的Cmax、AUC增高而Cl/F、V/F减少 ;Cef2 5mg·kg- 1+Pro 10 0mg·kg- 1组各参数 (除Cl/F外 )与Cef 5 0mg·kg- 1组差异不显著。结论 :Pro可明显改变Cef的药动学 ,在实验剂量范围内其影响程度与丙磺舒剂量有关。Cef 2 5mg·kg- 1联用Pro10 0mg·kg- 1可产生Cef 5 0mg·kg- 1的血药水平。 AIM: To observe the effects of proben-ecid of different doses on pharmacokinetics of cefaclor and to provide the basis of their co-adiministration. METHODS: 30 rabbits were randomly divided into 5 groups: Cef 50 mg·kg -1, Cef 50 mg·kg -1+Pro 50 mg·kg -1,Cef 50 mg·kg -1+Pro 100 mg·kg -1,Cef 50 mg·kg -1+Pro 200 mg·kg -1,Cef 25 mg·kg -1+Pro 100 mg·kg -1. The blood samples were drawn from thigh vein after IG and the concentrations of cefaclor were determined by HPLC. Pharmacokinetics parameters were calculated by NDST procedure. RESULTS: In groups with Cef 50 mg·kg -1, C max and AUC of cefaclor increased, and Vd/F and Cl/F decreased progressively with the adding probenecid. There was no significant difference between Cef 25 mg+Pro 100 mg and Cef 50 mg·kg -1 in each parameter except Cl/F. CONCLUSION: Probenecid can remarkably alter the pharmacokinetics of cefaclor and the magnitude of the effects of probenecid is dependent on its dose in this trial. Cef 25 mg·kg -1 with Pro 100 mg·kg -1 can reach the same blood concentration as Cef 50 mg·kg -1 alone.
出处 《中国临床药理学与治疗学》 CAS CSCD 2002年第2期130-133,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 头孢克罗 丙磺舒 药物代谢动力学 HPLC cefaclor probenecid pharmacokinetics HPLC
  • 相关文献

参考文献14

  • 1高永贵.头孢克洛的临床应用[J].天津药学,2000,12(3):20-21. 被引量:12
  • 2Levison ME,Santoro J,Ayarwal BN.In vitro activity and pharmacokinetics of cefaclor in normal volunteer and patients with renal failure[J].Postgrad Med J,1979;55 (Supple4):12-6
  • 3Kitaura T,Tsukiai S,Miyake K,et al.Ocular Pharmacokinetics of Latamoxef and cefaclor in rabbits[J].J Pharmacobiodyn ,1988; 11:694-9
  • 4郭蓓宁,张菁,王磊,张婴元.国产头孢克洛临床药代动力学研究和相对生物利用度测定[J].中国新药杂志,2000,9(7):466-467. 被引量:6
  • 5程能能 孙瑞元.新药数据的统计处理及NDST程序[J].皖南医学院学报,1994,13:28-30.
  • 6Cunningham RF,Israili ZH,Dayton PG.Clinical Pharmacokineftcs of probenecid[J].Clin Pharmacokinet,1981;6:135-51
  • 7Tsuji A,Terasai T,Tanai I,et al.In vitro evidence for carrier-mediated uptake of B-lactam antibiotics through organic anion transport systems in rat kidney and liver[J].J Pharmacol Exp Ther,1990;253:315-20
  • 8Bonate PL,Reith K,Weir S.Drug interactions at the renal level[J].Clin pharmacokinet,1998;34:375-404
  • 9Barbhaiya RH,Shukla UA,Gleason CR,et al.Phase I study of multiple-dose cefprozil and comparsion with cefaclor[J].Antimicrob Agens Chemother,1990;34:1198-203
  • 10Santoro J,Agarwal BN,Martinelli R,et al.Pharmacology of cefaclor in normal volunteers and patients with renal failure[J].Antimicrob Agens Chemother,1978;13:951-4

二级参考文献12

共引文献29

同被引文献4

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部